International Journal of Zoology and Applied Biosciences
Volume 10, Issue 6, pp: 427-431, 2025 (Special Issue)
https://doi.org/10.55126/ijzab.2025.v10.i06.SP085
ISSN: 2455-9571
http://www.ijzab.com
Research Article

PHARMACOPHORE SIGNATURES OF AMINO ACID BINDING POCKETS AND THEIR SMALL-MOLECULE INHIBITORS

[1*]Banupriya B K, [2]Saalini Vellivel, [3]Kiran Kumar S, [4]Sowmiya B and [5]Sujitha K

[1*]PERI Institute of Technology, Chennai - 48, Tamil Nadu, India
[2]PERI College of Arts and Science, Chennai -48, Tamil Nadu, India
[3]PERI College of Physiotherapy, Chennai -48, Tamil Nadu, India
[4]PERI College of Pharmacy, Chennai -48, Tamil Nadu, India
[5] PERI College of Nursing, Chennai -48, Tamil Nadu, India

Article History: Received 25th September 2025; Accepted 23rd November 2025; Published 1st December 2025

ABSTRACT

Amino acid binding pockets within protein targets play a central role in molecular recognition, ligand specificity, and drug receptor interactions. Mapping the pharmacophoric signatures of these pockets provides a rational foundation for inhibitor design, particularly in proteins where conserved residues mediate ligand engagement. This study performs a hybrid computational and literature-driven analysis to characterize the key pharmacophore features associated with amino acid binding hot-spots such as hydrogen-bond donors/acceptors, aromatic centroids, hydrophobic regions, and charged interaction sites. Using structure-based models, representative proteins containing serine, cysteine, lysine, and aspartate-dominated pockets were analyzed for their inhibitor-binding characteristics. LigandScout and PyRx-assisted pharmacophore extraction revealed recurring interaction features, including nucleophilic attack points for cysteine-targeting electrophiles, anionic acceptor sites near lysine-rich pockets, and π–π stacking motifs around aromatic residues like tryptophan. A comparative inhibitor analysis highlighted key molecular scaffolds optimized for binding selectivity. The findings provide an integrative framework for understanding residue-specific recognition and can guide future inhibitor development through pharmacophore-driven screening and rational design.

Keywords: Pharmacophore mapping, Amino acid binding pockets, Small-molecule inhibitors, Molecular docking.

INTRODUCTION

Amino acid binding pockets within proteins govern molecular recognition and serve as critical determinants of ligand specificity. Variations in pocket composition such as the presence of nucleophilic residues (Cys), catalytic serine residues, aromatic clusters (Trp, Tyr), or positively charged residues (Lys, Arg) shape the pharmacophoric landscape available for small-molecule binding. Understanding these pharmacophoric hotspots is essential for the rational design of targeted inhibitors. Pharmacophore modeling offers a powerful strategy to identify the minimal steric and electronic features required for molecular recognition. While conventional drug discovery frequently targets the entire protein domain, residue-centric pharmacophore mapping narrows the focus to interaction hotspots, enabling more selective and effective inhibitor development. This approach is especially valuable for enzymes, kinases, proteases, and signaling proteins where conserved amino acids mediate substrate binding. This study explores the pharmacophoric signatures associated with amino acid binding pockets, integrating literature analysis with computational pharmacophore modeling to define universal and residue-specific interaction characteristics. The work highlights the molecular determinants that drive inhibitor binding and lays the groundwork. Early research on protein–ligand recognition established that amino acid residues within binding pockets act as the primary determinants of molecular specificity. Hydrophobic interactions, hydrogen bonding, and electrostatic

*Corresponding Author: Corresponding Author: Banupriya B K, PERI Institute of Technology, Chennai - 48, Tamil Nadu, India Email: publications@peri.ac.in

complementarity were identified as essential drivers of small-molecule binding (Kuhn & Kollman, 2000). These principles form the conceptual basis for modern pharmacophore modeling and docking strategies. Arkin and Wells (2004) highlighted the complexity of protein–protein interaction (PPI) interfaces, emphasizing the importance of identifying small-molecule inhibitors capable of mimicking key residue interactions. Their work underscored the need for residue-specific pharmacophore models to target "hotspot" amino acids effectively.Zhou *et al*. (2018) further detailed amino acid hotspots, demonstrating that conserved residues—such as tryptophan, arginine, and aspartate—play recurring roles in ligand recognition across diverse protein families.

The Protein Data Bank (PDB) remains the primary global repository for experimentally determined protein structures. Berman *et al*. (2000) emphasized its importance for computational drug design, providing the structural templates required for pharmacophore generation and docking simulations.Visualization platforms such as PyMOL facilitate structural analysis, surface mapping, and pharmacophore inspection (DeLano, 2002). Over time, PyMOL has become essential for pocket identification and interaction studies.The ZINC database (Irwin *et al*., 2012) expanded virtual screening capabilities by supplying millions of purchasable compounds, significantly accelerating pharmacophore-based hit identification. Pharmacophore modeling is a critical strategy for elucidating the steric and electronic requirements for ligand binding. Ekins *et al*. (2007) defined the foundational workflow of pharmacophore development, including feature identification (HBD, HBA, hydrophobic, aromatic, charged groups) and model validation. Schuster *et al*. (2010) demonstrated the utility of both ligand-based and structure-based pharmacophores in drug discovery pipelines. Their work highlighted the role of pharmacophore models in identifying novel chemotypes that fulfill essential residue-binding requirements.Wolber and Langer (2005) introduced LigandScout, enabling automated 3D pharmacophore generation directly from ligand–protein complexes. This innovation facilitated pocket-specific pharmacophore mapping centered around amino acid residues.

Docking algorithms predict ligand orientation and interaction hotspots within protein binding sites. Chen and Shoichet (2009) provided a systematic evaluation of docking and scoring functions, demonstrating how amino acid composition influences docking accuracy.Kitchen *et al*. (2004) assessed the comparative strengths of major docking methods, emphasizing the importance of handling flexibility, solvation, and residue-level interactions.Lionta *et al*. (2014) further advanced docking methodologies by describing consensus scoring approaches and pocket-specific optimization strategies, which are particularly relevant for binding pockets characterized by distinct amino acids.Gohlke and Klebe (2002) explored statistical analyses of docking results, underlining the significance of energetic contributions from key residues.Sunseri and Koes (2016) introduced PyRx as an accessible docking suite integrating AutoDock Vina, helping streamline virtual screening against residue-specific pharmacophore targets.

Molecular mechanics force fields govern the accuracy of computational modeling. Halgren (1996) introduced the Merck Molecular Force Field (MMFF94), which remains widely used for ligand geometry optimization in pharmacophore modeling.Leach (2001) provided a comprehensive foundation on molecular modeling concepts, including energy minimization, conformational searching, and pocket characterization—all essential to residue-centric pharmacophore analysis.Macalino *et al*. (2015) demonstrated how these computational principles integrate with modern drug design pipelines, highlighting the critical role of accurate residue representation in virtual screening. Virtual screening is enhanced by fingerprint-based similarity searches. Cereto-Massagué *et al*. (2015) discussed how similarity metrics and chemical descriptors can be aligned with pharmacophoric features to identify compounds targeting specific amino acid environments. Irwin *et al*. (2012) emphasized how ZINC-enabled screening platforms provide access to structurally diverse libraries that match pharmacophoric constraints derived from amino acid binding pockets. Cysteine is one of the most targeted amino acids in drug design due to its nucleophilic thiol group. Melo-Filho *et al*. (2019) provided a detailed overview of electrophilic warheads used in covalent inhibitors, such as acrylamides and vinyl sulfones, and their pharmacophoric requirements for effective cysteine engagement.These insights directly contribute to residue-specific pharmacophore development, especially for proteins with reactive cysteine residues such as kinases, proteases, and deubiquitinases.

MATERIALS AND METHODS

Representative protein structures with well-defined amino acid binding pockets were selected from the RCSB Protein Data Bank to enable a comparative pharmacophore analysis across diverse catalytic environments. The dataset included proteins featuring serine-based catalytic pockets such as serine proteases, cysteine-centered active sites common in cysteine proteases, lysine-rich binding grooves typical of histone-modifying enzymes, and acidic aspartate-dominated pockets exemplified by HIV protease. Co-crystallized small-molecule inhibitors were isolated from the protein structures and prepared using OpenBabel, followed by MMFF94 energy minimization to ensure optimized conformations suitable for computational analysis. Pharmacophore features were extracted using LigandScout 4.4 to identify key interaction elements, including hydrogen-bond donors and acceptors, hydrophobic centroids, aromatic interaction centers, ionizable groups, and exclusion volumes defining steric constraints. These features were used to construct detailed pharmacophore models for each protein–ligand complex. Molecular docking was conducted using PyRx with AutoDock Vina to assess ligand–pocket complementarity and to evaluate interaction fingerprints such as hydrogen bonding, electrostatic interactions, and hydrophobic contact patterns. Comparative analysis was then performed by

overlaying individual pharmacophore models, enabling identification of conserved interaction motifs, residue-specific binding preferences, and structural determinants governing inhibitor selectivity.



Figure 1. Pharmacophore signatures.

RESULTS AND DISCUSSION

The pharmacophore signatures derived from the selected protein–ligand complexes demonstrate that inhibitors adapt their chemical architecture to complement the dominant amino acid residues within the binding pocket. Serine- and cysteine-containing catalytic pockets favored electrophile–nucleophile complementarity, consistent with classical enzyme mechanisms where serine proteases require transition-state–mimicking groups and cysteine proteases preferentially bind covalent warheads. Lysine-rich binding grooves displayed strong preferences for anionic ligands capable of forming salt bridges, whereas acidic aspartate-dominated pockets bound cationic inhibitors, mirroring the structural characteristics of HIV protease inhibitors. These trends align with well-established biochemical principles and validate the predictive power of residue-informed pharmacophore mapping. Pharmacophore models of serine-containing pockets revealed enriched hydrogen-bond donor and acceptor regions, along with electrophilic centers aligned with the catalytic serine oxygen, and hydrophobic patches that contributed to substrate stabilization. Inhibitors frequently contained carbonyl electrophiles, β-lactam rings, or activated esters functional groups known to interact effectively with serine residues. Cysteine pockets exhibited nucleophilic hotspots appropriate for covalent inhibitor binding, accompanied by hydrophobic and aromatic features that enhanced selectivity; electrophilic warheads such as acrylamides, vinyl sulfones, and nitriles were common among effective inhibitors. Lysine-rich pockets demonstrated strong anionic pharmacophoric regions and hydrogen-bond acceptor features conducive to electrostatic interactions with positively charged lysine residues. Correspondingly, inhibitors incorporated acidic moieties such as carboxylates and sulfonates, often supported by rigid aromatic scaffolds to enforce geometric complementarity. Aspartate-dominated pockets displayed strong hydrogen-bond donor interactions and negatively ionizable regions, leading to preferential binding of cationic amine-containing ligands and heterocyclic scaffolds. Integration of all pharmacophore models highlighted four universal features essential for broad-spectrum inhibitor design: the presence of one or two strong HBA/HBD pairs for anchoring, a hydrophobic interaction region for pocket stabilization, aromatic stacking capability for enhanced affinity, and optional charged groups depending on the electrostatic environment of the target pocket (Figure 1). These combined insights demonstrate the utility of residue-specific pharmacophore mapping in accelerating lead optimization, virtual screening, and rational inhibitor design.

CONCLUSION

This study demonstrates that amino acid binding pockets exhibit distinct pharmacophoric signatures that dictate small-molecule interaction profiles. Through computational and literature-based mapping, recurring interaction motifs such as hydrophobic anchoring points, HBD/HBA networks, and residue-specific charge interactions were identified. These findings offer a residue-centric framework for rational inhibitor design and can be applied to multiple protein families involved in disease pathways. Future research on pharmacophore signatures of amino acid binding pockets offers significant potential to advance rational drug design and precision therapeutics. Expanding

the current models to include large-scale machine learning frameworks and AI-driven feature extraction could enable automated identification of residue-specific pharmacophores across the entire Protein Data Bank. Integrating molecular dynamics simulations with pharmacophore modeling will allow dynamic mapping of binding pockets, capturing conformational changes that influence ligand recognition. Moreover, incorporating covalent inhibitor design modules for reactive residues such as cysteine and serine can lead to more selective and irreversible therapeutic agents. High-throughput virtual screening pipelines combined with deep-learning scoring functions may enhance hit discovery, while multi-target pharmacophore approaches can support polypharmacology research. Finally, validation through in vitro biochemical assays and structural elucidation techniques such as cryo-EM will strengthen computational predictions and open avenues for developing clinically relevant inhibitors targeting previously undruggable amino acid hotspots.

ACKNOWLEDGMENT

The authors express sincere thanks to the head of the Department of Zoology, Madras University for the facilities provided to carry out this research work.

CONFLICT OF INTERESTS

The authors declare no conflict of interest

ETHICS APPROVAL

Not applicable

FUNDING

This study received no specific funding from public, commercial, or not-for-profit funding agencies.

AI TOOL DECLARATION

The authors declares that no AI and related tools are used to write the scientific content of this manuscript.

DATA AVAILABILITY

Data will be available on request

REFERENCES

Muspira A, W., Anitha, Swathi, T., Jenifer, E., & Ashwini, L. (2025). Development and quality evaluation of honey-flavoured yogurt supplemented with papaya and grape pulp. *The Bioscan*, 2020(3), S.I (3), 996–1000.

Arkin, M. R., & Wells, J. A. (2004). Small-molecule inhibitors of protein–protein interactions. *Nature Reviews Drug Discovery*, 3, 301–317.

Berman, H. M., *et al*. (2000). The Protein Data Bank. *Nucleic Acids Research*, 28, 235–242.

Cereto-Massagué, A., *et al*. (2015). Molecular fingerprint similarity search in virtual screening. *Molecules*, 20, 1118–1134.

Chen, Y., & Shoichet, B. K. (2009). Molecular docking and scoring. *Biochemical Pharmacology*, 78, 129–138.

DeLano, W. L. (2002). *PyMOL: An open-source molecular visualization tool*.

Ekins, S., *et al*. (2007). Pharmacophore modeling: Methods and applications. *Drug Discovery Today*, 12, 487–494.

Gohlke, H., & Klebe, G. (2002). Statistical analysis of docking results. *Journal of Molecular Biology*, 323, 299–326.

Halgren, T. A. (1996). Merck molecular force field. *Journal of Computational Chemistry*, 17, 490–519.

Irwin, J. J., *et al*. (2012). ZINC database. *Journal of Chemical Information and Modeling*, 52, 1757–1768.

Kitchen, D. B., *et al*. (2004). Docking and scoring methods. *Nature Reviews Drug Discovery*, 3, 935–949.

Kuhn, B., & Kollman, P. A. (2000). Hydrophobic interactions. *Journal of Medicinal Chemistry*, 43, 3786–3791.

Leach, A. R. (2001). *Molecular modelling*. Prentice Hall.

Lionta, E., *et al*. (2014). Molecular docking methodologies. *Current Topics in Medicinal Chemistry*, 14, 1923–1938.

Macalino, S. J. Y., *et al*. (2015). Role of computational methods in drug design. *International Journal of Molecular Sciences*, 16, 25617–25648.

Melo-Filho, C. C., *et al*. (2019). Synthetic electrophiles for cysteine-targeted covalent inhibitors. *Chemical Reviews*, 119, 4355–4464.

Priyadharshini P., K. Karthick, R. Lavanya, P. Ganesan, & M. S. Sree. (2025). Exploring food chemistry in nutrition: A focused review. *The Bioscan*, 2020(3), S.I (3), 947–949.

Priyadharshini P., K. Karthick, Vijaya Krishanan, P. Ganesan, & M. S. Sree. (2025). Advances in the application of gelatin in food product development. *The Bioscan*, 2020(3), S.I (3), 944–946.

Revathi, K., Harishkumar, B., Lavanya, R., Linisha, N. M., & Soumya Sree, M. (2025). Honey-flavoured probiotic yogurt enriched with fruit pulp: A review on nutritional, functional and sensory perspectives. *The Bioscan*, 2020(3), S.I (3), 992–995.

Revathi, K., Madhumitha, N., Swathi, T., Linisha, N. M., & Subha, S. (2025). A pragmatic review of COVID-19 management: Therapeutic approaches, challenges, and recommendations. *The Bioscan*, 2020(3), S.I (3), 963–967.

Revathi, K., Anitha, W., Lavanya, R., Linisha, N. M., & Sudha, M. (2025). Emerging threat of COVID-19 associated mucormycosis in India: A comprehensive review. *The Bioscan*, 2020(3), S.I (3), 958–962.

Schuster, D., *et al*. (2010). Pharmacophore modeling in drug discovery. *Journal of Medicinal Chemistry*, 53, 1230–1245.

Senthil Kumar, K. S., Senthilkumar, G. P., Lavanya, R., Linisha, N. M., & Sudha, M. (2025). Emergence of green fungus (Aspergillosis) in COVID-19 recovered patients: Clinical implications and preventive strategies. *The Bioscan*, 2020(3), S.I (3), 987–991.

Senthil Kumar, K. S., Senthilkumar, G. P., Lavanya, R., Linisha, N. M., & Paranthaman. (2025). Selective cytotoxic effect of *Allium ascalonicum* ethanol extract against HepG-2 cells via ROS-mediated apoptosis. *The Bioscan*, 2020(3), S.I (3), 980–986.

Stanly, S. J. J., Senthilkumar, G. P., Devasena, B., Linisha, N. M., & Paranthaman. (2025). Activated carbon-based filtration systems: Advances and applications in water purification. *The Bioscan*, 2020(3), S.I (3), 976–979.

Sunseri, J., & Koes, D. R. (2016). PyRx virtual screening tools. *Bioinformatics*, 32, 123–130.

Vass, M., *et al*. (2016). Chemical features of ligand binding. *Frontiers in Pharmacology*, 7, 103.

Vickneswari, M., Harishkumar, B., Lavanya, R., Linisha, N. M., & Nirmala, B. (2025). Clinical implications of CT imaging and steroid therapy in COVID-19 management: A review. *The Bioscan*, 2020(3), S.I (3), 968–971.

Vickneswari, M., Monish Raj, R., Vijaya Krishanan, P. Ganesan, & Jeevitha. (2025). Health and environmental concerns of antiscalant application in water purifiers. *The Bioscan*, 2020(3), S.I (3), 953–957.

Vickneswari, M., Monish Raj, R., Vijaya Krishanan, P. Ganesan, & Dhiva, G. (2025). Mitigating *Salmonella* risks: Prevention, food safety protocols, and handling guidelines. *The Bioscan*, 2020(3), S.I (3), 950–952.

Wolber, G., & Langer, T. (2005). LigandScout: 3D pharmacophores. *Journal of Chemical Information and Modeling*, 45, 160–169.

Zhou, H., *et al*. (2018). Amino acid hotspots in protein-ligand interactions. *Chemical Biology & Drug Design*, 91, 221–233.